VI Partners related stories
All articles and analysis
VC-backed JenaValve appoints new CEOMunich, Germany and Irvine, California-based JenaValve Technology, a provider of transcatheter aortic valve implantation systems that treat aortic valve disease, has named Dr. Victoria E. Carr-Brendel as CEO. The appointment is effective immediately. Previously, Dr. Carr-Bendel served as general manager of Boston Scientific’s Bayer Interventional business. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
- Genkyotex nets $21 mln Series D
Genkyotex, which develops selective NOX inhibitors, has closed $21 million in Series D funding. NeoMed Management, VI Partners and BioMedInvest led the round with participation from Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners. In conjunction with the funding, Dr. Claudio Nessi of NeoMed has been added to Genkyotex’s board.
- Nexthink reels in $14.5 mln Series D
Nexthink, a Swiss provider of IT analytics, has raised $14.5 million in Series D funding. Auriga Partners led the round with participation from Gilles Queru, VI Partners and Mannai Corp.
- VC-backed JenaValve Technology names CTO
JenaValve Technology has hired Dr. Stefan Schreck as chief technology officer. The apointment is effective immediately. Schreck is the former vice president of technology and later chief technology officer at Endologix. Based in Munich, Germany and Irvine, Calif., JenaValve Technology is a provider of transcatheter aortic valve implantation systems that treat aortic valve disease. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
- VC-backed JenaValve Technology hires CEO
JenaValve Technology said Monday that it has named David J. Drachman as CEO. The appointment is effective immediately. Drachman is the former president and CEO of AtriCure. Based in Munich, Germany and Irvine, Calif., JenaValve Technology is a provider of transcatheter aortic valve implantation systems that treat aortic valve disease. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
- VC-backed JenaValve Technology hires CEO
JenaValve Technology said Monday that it has named David J. Drachman as CEO. The appointment is effective immediately. Drachman is the former president and CEO of AtriCure. Based in Munich, Germany and Irvine, Calif., JenaValve Technology is a provider of transcatheter aortic valve implantation systems that treat aortic valve disease. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
- Sequana Medical raises Series C
Sequana Medical has raised CHF 23 million ($26.2 million) in a Series C preferred share financing round led by Life Science Partners and co-led by NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund and Capricorn Venture Partners. The business is a Swiss medical device company.
- St. Jude Medical Buys VC-Backed Endosense
St. Jude Medical, a St.Paul, Minnesota-based provider of medical devices, said Monday that it has acquired Endosense for an initial payment of $170 million. St. Jude Medical will also pay an additional $161 million for the acquisition. BofA Merrill Lynch is serving as financial advisor to St. Jude Medical for the transaction while Perella Weinberg Partners is advising Endosense. Based in Geneva, Switzerland, Endosense, is a medical technology company focused on treating cardiac arrhythmias. It is backed by Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital.
- Edimer Pharmaceuticals Raises $18 Mln in Series B Financing
Edimer Pharmaceuticals said Tuesday that it has closed $18 million in Series B financing. The lead investor was New Enterprise Associates. New investor Sanofi-Genzyme BioVentures and previous investors Third Rock Ventures and VI Partners also participated in the round. In addition to the news about funding, David Mott will join Edimer's board. Based in Cambridge, Mass., Edimer Pharmaceuticals is a biotech company.
- Endosense Scores $4.3M Add-On
Endosense, a Geneva-based developer of sensing technology focused on catheter ablation for the treatment of cardiac arrhythmias, has raised $4.3 million in new funding, bringing its Series C round to $44.6 million. Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital.